The successful commercialisation journey of Aberdeen medtech business Sirakoss will be the focus for the next ONE Life Sciences Network meeting on 9 December.
The session will chart the company’s development from research innovation through funding rounds to key product regulatory approvals, acquisition and clinical roll-out.
Sirakoss was spun out from the University of Aberdeen in 2011 and acquired by Swedish firm OssDsign earlier this month.
The speakers will be Prof Iain Gibson, co-founder of Sirakoss and Professor of Acellular Regenerative Medicine at the University of Aberdeen, and Dr Tom Buckland, chief strategy officer at Sirakoss.
Sirakoss has successfully developed Osteo3 ZP Putty, a nanosynthetic bone graft substitute to facilitate bone repair, which recently received 510(k) marketing clearance from the US Food and Drug Administration (FDA). Sirakoss’ highly differentiated putty has been designed to provide surgeons with an innovative and easy-to-use product for filling voids during spine and trauma bone grafting procedures. The product complements OssDsign’s craniomaxillofacial portfolio and commercial activities in the US are expected to begin immediately.
The meeting, held via Zoom, will include presentations and Q&A, an update from Opportunity North East on action and investment in the sector, including the £40 million BioHub project on the Foresterhill Health Campus, and virtual networking.
Prof Stephen Logan, chair of the ONE Life Sciences sector board and BioAberdeen board, will chair the meeting.
You can register for the session here.
Your privacy matters to us so if you want to find out more on how we keep your data safe, view our Privacy Notice or talk to ONE direct.